Want to see RVTY full AI Analyst Report?
Top Page
Revvity
(NYSE:RVTY)
Select Model
Select Model
Rating:71Outperform
Price Target:
$127.00
▲(14.96% Upside)
Action:Reiterated
Date:08/04/26
RVTY scores well on improving financial performance (re-accelerating revenue and strong free cash flow) and supportive technical momentum (price above key moving averages with positive MACD). The score is held back by a high P/E and low dividend yield, plus earnings-call risks around software cadence volatility and the non-recurring nature of part of the recent upside.
Positive Factors
Recurring consumables and installed-base model
Revvity's mixed model—capital instruments plus high-margin, repeat consumables and service contracts—creates a durable recurring revenue base that supports predictable cash flows as installed instruments drive repeat reagent and service purchases over multi-year cycles.
Negative Factors
Software revenue volatility (Signals)
Large quarter-to-quarter swings in Signals ARR and revenue create uncertainty for recurring software growth, complicating forecasting and margin outlook. Software volatility weakens predictability of high-margin revenue streams that management frames as a multi-year growth driver.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring consumables and installed-base model
Revvity's mixed model—capital instruments plus high-margin, repeat consumables and service contracts—creates a durable recurring revenue base that supports predictable cash flows as installed instruments drive repeat reagent and service purchases over multi-year cycles.
Read all positive factors
Revvity Key Performance Indicators (KPIs)
Any
Revenue by Geography
Breaks down where sales come from around the world, revealing dependence on particular markets and exposure to regional growth or regulatory risk. Shifts between regions signal where Revvity is gaining share or facing headwinds and can affect currency and supply‑chain sensitivity.
Breaks down where sales come from around the world, revealing dependence on particular markets and exposure to regional growth or regulatory risk. Shifts between regions signal where Revvity is gaining share or facing headwinds and can affect currency and supply‑chain sensitivity.
Data provided by:
The Fly
The FlyRevvity (RVTY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$13.11B
Dividend Yield0.24%
Average Volume (3M)1.34M
Price to Earnings (P/E)55.6
Beta (1Y)1.01
Revenue Growth4.05%
EPS Growth-10.40%
CountryUS
Employees11,000
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)2.10
Shares Outstanding111,586,400
10 Day Avg. Volume1,245,625
30 Day Avg. Volume1,338,396
Financial Highlights & Ratios
PEG Ratio-3.41
Price to Book (P/B)1.52
Price to Sales (P/S)3.85
P/FCF Ratio21.63
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$115.14Price Target Upside4.23% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)5.24
Revenue Forecast (FY)$2.83B
Revvity Business Overview & Revenue Model
Company Description
Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, cate...
How the Company Makes Money
Revvity makes money primarily by selling products and services across life science research and diagnostics workflows. Its revenue model is a mix of (1) capital equipment/instrument sales (e.g., laboratory instruments and automation platforms) and...
Revvity Earnings Call Summary
Earnings Call Date:Aug 04, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 02, 2026
Earnings Call Sentiment Positive
The call presented a generally positive operational and financial picture: revenue and EPS beat with upgraded full-year guidance, strong Diagnostics performance, accelerating high-content instrument orders and robust cash flow and balance sheet improvements. Key near-term weaknesses include a sizable decline in Signals software revenue this quarter, some production/timing constraints that shifted instrument revenue into Q3, and portions of the quarter's outperformance tied to one-time tariff refunds and tax timing. Management plans reinvestments of a portion of one-time benefits while highlighting new software capabilities and AI-driven demand as multi-year growth drivers—though the AI opportunity is still early and not fully quantifiable.Positive Updates
Top-line and Organic Growth Beat
Q2 pro forma revenue of $711M with 3% pro forma organic growth, slightly above the high end of guidance; full-year organic growth guidance raised to 4%–5% (from 3%–4%).
Negative Updates
Life Sciences Segment Weakness
Life Sciences revenue $359M, organic decline ~3% in Q2 (reported -2%); Life Sciences Solutions modest low-single-digit growth and Signals software declined ~20% year-over-year due to contract timing and difficult comps.
Read all updates
Q2-2026 Updates
Positive
Negative
Top-line and Organic Growth Beat
Q2 pro forma revenue of $711M with 3% pro forma organic growth, slightly above the high end of guidance; full-year organic growth guidance raised to 4%–5% (from 3%–4%).
Read all positive updates
Company Guidance
Revvity raised its 2026 pro forma outlook: organic growth now 4–5% (vs. 3–4%), with FX contributing ~50 bps and the ACD/Labs acquisition ~75 bps, implying pro forma revenue of $2.83–$2.86B; pro forma adjusted operating margin is now 28.7% (up 30 bps) and pro forma adjusted EPS is $5.30–$5.40 (up $0.10), with net interest & other expense ~ $90M, a full‑year tax rate of ~18%, diluted share count ~112M, and a target gross leverage <3x and net leverage approaching 2x by year‑end (net debt/EBITDA was 2.5x at quarter end). For Q3 they guide organic growth of 4–6%, revenue of $685–$700M, ~29% pro forma adjusted operating margin, net interest ~$23M, a Q3 tax rate of ~19% and Q3 EPS ~24% of the full‑year outlook; management noted $16M of tariff refunds in Q2 (about half of Q2 EPS upside) and said most refunds have been received with any additional amounts expected to be immaterial.Revvity Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
68
Positive
Cash Flow
74
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.91B | 2.86B | 2.76B | 2.75B | 3.31B | 3.83B |
| Gross Profit | 1.52B | 1.52B | 1.32B | 1.32B | 1.76B | 2.28B |
| EBITDA | 767.00M | 662.72M | 840.25M | 713.56M | 1.18B | 1.62B |
| Net Income | 237.55M | 241.68M | 295.83M | -118.38M | 569.18M | 943.16M |
Balance Sheet | ||||||
| Total Assets | 12.05B | 12.17B | 12.39B | 13.56B | 14.13B | 15.00B |
| Cash, Cash Equivalents and Short-Term Investments | 1.02B | 919.87M | 1.16B | 1.60B | 454.36M | 603.32M |
| Total Debt | 3.34B | 3.52B | 3.33B | 4.07B | 4.60B | 5.16B |
| Total Liabilities | 4.82B | 4.92B | 4.73B | 5.69B | 6.75B | 7.86B |
| Stockholders Equity | 7.23B | 7.25B | 7.67B | 7.87B | 7.38B | 7.14B |
Cash Flow | ||||||
| Free Cash Flow | 559.34M | 508.25M | 541.65M | 9.90M | 594.18M | 1.32B |
| Operating Cash Flow | 628.86M | 581.78M | 628.30M | 91.27M | 679.81M | 1.41B |
| Investing Cash Flow | -83.26M | -17.35M | 776.16M | 1.31B | -132.85M | -4.11B |
| Financing Cash Flow | -503.44M | -855.05M | -1.13B | -947.12M | -661.80M | 2.94B |
Revvity Technical Analysis
Positive
110.47
Price Trends
108.99
Positive
100.61
Positive
99.72
Positive
Market Momentum
2.22
Negative
61.28
Neutral
91.49
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RVTY, the sentiment is Positive. The current price of 110.47 is below the 20-day moving average (MA) of 112.90, above the 50-day MA of 108.99, and above the 200-day MA of 99.72, indicating a bullish trend. The MACD of 2.22 indicates Negative momentum. The RSI at 61.28 is Neutral, neither overbought nor oversold. The STOCH value of 91.49 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RVTY.
Revvity Risk Analysis
Revvity disclosed 24 risk factors in its most recent earnings report. Revvity reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Revvity Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | $8.91B | 22.03 | 11.28% | 6.38% | 2.96% | 9.52% | |
74 Outperform | $26.05B | 24.57 | 14.49% | 1.46% | 9.87% | 12.51% | |
71 Outperform | $13.11B | 55.64 | 3.27% | 0.25% | 4.05% | -10.40% | |
71 Outperform | $29.09B | 35.28 | 31.08% | ― | 4.97% | -31.78% | |
60 Neutral | $21.41B | -45.05 | 211.46% | ― | 42.74% | -4.60% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
RVTY
Revvity
116.84
26.31
29.06%
ILMN
Illumina
190.89
90.78
90.68%
QGEN
Qiagen
42.95
-6.04
-12.33%
DGX
Quest Diagnostics
234.40
57.73
32.68%
GH
Guardant Health
157.21
98.33
167.00%
Revvity Corporate Events
Business Operations and StrategyFinancial DisclosuresM&A Transactions
Revvity posts solid Q2 2026 earnings growth
Positive
Aug 4, 2026
Revvity reported its second-quarter 2026 results on August 4, 2026, posting revenue of $730 million, up slightly from $720 million a year earlier, with GAAP earnings per share from continuing operations rising to $0.48 from $0.47. Adjusted EPS cli...
Business Operations and StrategyFinancial DisclosuresM&A Transactions
Revvity Posts Strong Q1 Results and Updates 2026 Outlook
Positive
May 5, 2026
Revvity reported first-quarter 2026 results on May 5, 2026, with revenue rising to $711 million from $665 million a year earlier and GAAP EPS from continuing operations improving to $0.37 from $0.35. Adjusted EPS from continuing operations increas...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.